swH1, Swine H1 Influenza (2009 H1N1) Reverse Primer
产品概述技术指标订购信息服务支持
详细描述：
2009年H1N1（新型流感A）ValuPanel™试剂*是LGC Biosearch Technologies的ValuPanel检测试剂系列的一部分。ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。
*仅供研究使用，不用于诊断程序
2009年H1N1鉴定获CDC授权**
作为被授权的鉴定2009 H1N1的寡核苷酸制造商，LGC Biosearch 2009 H1N1检测Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分H1N1相关病毒株。2009 H1N1 ValuPanel试剂含有基于以下病毒株遗传鉴定的探针和引物：
流感A
猪流感A
猪H1流感
人类RNase P（提取对照）
这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。
** CDC不认可产品或服务。
应对公共卫生紧急情况
为了响应2009年H1N1的爆发，美国食品和药物管理局（FDA）向CDC发布了紧急使用授权（EUA），立即使用美国疾病控制和预防中心（CDC）设计的qRT-PCR方法检测分析2009年H1N1。CDC很快开发了2009 H1N1Panel，以检测和识别新型流感A（H1N1）病毒的病例，并且是个面向公共卫生和其他合格实验室进行分子诊断试验的FDA授权分销商。Biosearch Technologies通过提供H1N1检测Panel所需的探针和引物参与了对流感大流行的快速反应。
世界卫生组织（WHO）在网上公布了其流感A（H1N1）qRT-PCR的CDC方案，列出了来自LGC Biosearch的Black HoleQuencher®（BHQ®-1）染料作为所有其所列探针的猝灭剂。
The 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains.
*For Research Use Only. Not for use in diagnostic procedures.
2009 H1N1 Signatures Licensed from the CDC**
As a licensed manufacturer of oligonucleotides to resolve 2009 H1N1 signatures, LGC Biosearch Technologies is pleased to offer the same sequences in the form of ValuPanel Reagents. This panel consists of dual-labeled BHQ probes, a forward primer, and a reverse primer for use in real-time qPCR to discriminate H1N1-related viral strains. 2009 H1N1 ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains:
Influenza A
Swine Influenza A
Swine H1 Influenza A
Human RNase P (Extraction Control)
These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test.
**CDC does not endorse products or services.
Responding to a Public Health Emergency
In response to the outbreak of novel 2009 H1N1, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to the CDC for the immediate use of the Real-time RT-PCR Detection Assays for 2009 H1N1 designed by the US Centers for Disease Control and Prevention (CDC). The CDC readily developed the 2009 H1N1 Panel to detect and identify cases of the novel influenza A (H1N1) virus, and is the first FDA-authorized distributor of this molecular diagnostic test to public health and other qualified laboratories. Biosearch Technologies participated in the rapid response to the Flu pandemic by supplying the probes and primers necessary for the H1N1 detection panel.
Available to the public online, the World Health Organization (WHO) posted the CDC protocol of realtime RTPCR for influenza A (H1N1) which lists the Black Hole Quencher® (BHQ®-1) dye from LGC Biosearch as the quencher for all listed probes.
